Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pneumococcal vaccine
Biotech
GSK tips 12 blockbuster launches to soften HIV patent loss
GSK plans to launch at least 12 major products and deliver more than $48 billion in risk-adjusted sales by 2031.
Nick Paul Taylor
Jan 31, 2024 7:45am
Merck strides onto Pfizer’s turf with pivotal vaccine data
Nov 28, 2023 8:20am
Pfizer axes RSV, eczema, sickle cell and cancer drugs in cull
Aug 1, 2023 9:00am
Merck's next-gen pneumococcal shot secures 2 phase 3 wins
Jul 27, 2023 8:19am
Blackstone, Sutro ink royalty pact worth up to $390M biobucks
Jun 26, 2023 1:47pm
Vaxcyte's pneumococcal shot holds its own against Prevnar
Apr 17, 2023 11:10am